Page last updated: 2024-10-24

candesartan and Hypokalemia

candesartan has been researched along with Hypokalemia in 1 studies

candesartan: a nonpeptide angiotensin II receptor antagonist
candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.

Hypokalemia: Abnormally low potassium concentration in the blood. It may result from potassium loss by renal secretion or by the gastrointestinal route, as by vomiting or diarrhea. It may be manifested clinically by neuromuscular disorders ranging from weakness to paralysis, by electrocardiographic abnormalities (depression of the T wave and elevation of the U wave), by renal disease, and by gastrointestinal disorders. (Dorland, 27th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kim, MJ1
Kim, JH1
Kim, IY1
Lee, DW1
Lee, SB1

Other Studies

1 other study available for candesartan and Hypokalemia

ArticleYear
Reninoma Masked by the Use of an Angiotensin Receptor Blocker.
    Iranian journal of kidney diseases, 2016, Volume: 10, Issue:6

    Topics: Adenoma; Adult; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Delayed

2016